Ceftobiprole Medocaril: A New Fifth-Generation Cephalosporin

医学 菌血症 肺炎 重症监护医学 不利影响 临床试验 内科学 发热性中性粒细胞减少症 抗生素 中性粒细胞减少症 化疗 微生物学 生物
作者
Justin Zimmerman,Christopher Giuliano,Pramodini Kale-Pradhan
出处
期刊:Annals of Pharmacotherapy [SAGE Publishing]
卷期号:59 (7): 657-665 被引量:10
标识
DOI:10.1177/10600280241293773
摘要

Objective: The objective was to review the pharmacology, efficacy, and safety of intravenous ceftobiprole in the treatment of bloodstream infections, acute bacterial skin and skin structure infections (ABSSSIs), community-acquired pneumonia (CAP), and hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP). Data Sources: PubMed and ClinicalTrials.gov were searched using the following terms: ceftobiprole, ceftobiprole medocaril, ceftobiprole medocaril sodium, Zevtera, and BAL5788. Study Selection and Data Extraction: Articles published in English between January 1985 and August 15, 2024, related to pharmacology, safety, efficacy, and clinical trials were reviewed. Data Synthesis: Ceftobiprole has shown similar efficacy to comparator antibiotics in CAP, ABSSSIs, and bloodstream infections. Overall treatment success in patients with bacteremia was 69.8% and 68.7%; 91.3% and 88.1% with ABSSSIs and 86.6% and 87.4% with CAP in ceftobiprole and comparator groups, respectively. Finally, in the management of HAP and VAP, ceftobiprole was inferior in the VAP population. Ceftobiprole had a favorable safety profile with gastrointestinal adverse effects occurring more frequently than comparators. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Clinicians have limited options to treat multidrug-resistant infections. Ceftobiprole has demonstrated efficacy against causative pathogens in specific infections including methicillin-resistant Staphylococcus aureus bacteremia (SAB), ABSSSI, and CAP and may be considered a viable alternative. However, ceftobiprole’s impact on HAP, VAP, and febrile neutropenia needs to be further delineated. Conclusion: Ceftobiprole’s broad-spectrum activity makes it a viable option for treating patients hospitalized with CAP, ABSSSI, and SAB. Further studies are needed in severely ill HAP or VAP, febrile neutropenia, and pediatric patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爱学习的杨同学完成签到,获得积分10
刚刚
mety完成签到 ,获得积分10
1秒前
zyyy发布了新的文献求助30
1秒前
脑洞疼的应助被开朗的紫萱采纳,获得10
1秒前
小Q完成签到 ,获得积分10
1秒前
sdahjjyk发布了新的文献求助10
1秒前
1秒前
abs完成签到,获得积分20
2秒前
cdercder的应助被SCM采纳,获得10
2秒前
2秒前
强小强努力努力完成签到,获得积分10
3秒前
Lachryz发布了新的文献求助10
3秒前
凉介发布了新的文献求助10
3秒前
3秒前
笑点低幻珊完成签到,获得积分10
4秒前
积极的含灵完成签到,获得积分20
4秒前
先进的冰海完成签到,获得积分10
5秒前
刘龙完成签到,获得积分0
5秒前
123完成签到,获得积分10
5秒前
段启瑞完成签到,获得积分10
6秒前
桐桐的应助被王宏伟采纳,获得10
7秒前
天天快乐的应助被景胜杰采纳,获得20
7秒前
7秒前
水弘的应助被制作人采纳,获得10
7秒前
赘婿的应助被小马采纳,获得10
7秒前
元吉的应助被赵彬旭采纳,获得10
8秒前
呆萌尔风发布了新的文献求助20
8秒前
zhang发布了新的文献求助10
8秒前
Hello的应助被fzkls采纳,获得10
8秒前
Hsia完成签到,获得积分10
9秒前
9秒前
科研通AI6.4的应助被高高亦采纳,获得10
10秒前
零度完成签到 ,获得积分10
10秒前
11秒前
英俊的铭的应助被一点漾洋采纳,获得50
11秒前
冷艳的寒天的应助被jinrui采纳,获得10
11秒前
H欢完成签到,获得积分10
11秒前
稳稳完成签到,获得积分10
11秒前
Lucycomplex完成签到,获得积分10
11秒前
qi发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187592
求助须知:如何正确求助?哪些是违规求助? 9575705
关于积分的说明 21842471
捐赠科研通 7785407
什么是DOI,文献DOI怎么找? 3435057
关于科研通互助平台的介绍 2559461
邀请新用户注册赠送积分活动 2481952